Prognostic Impact of Programmed Death Ligand-1 Expression in Advanced Endometrial Cancer

Institut de Cancérologie de Lorraine80 enrolled

Overview

The aim of this study was to assess the frequency of PD-L1 expression in stage III-IV ECs and to investigate its correlation impact with progression-free survival (PFS), and clinicopathological features including microsatellite instability and quantified stromal and intraepithelial tumor-infiltrating CD8+ lymphocytes (TILs)

Study Type

OBSERVATIONAL

Enrollment

Conditions

Endometrial Cancer

Eligibility

Sex: FEMALEMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * All patients consecutively enrolled from January 2004 to December 2014 treated for Endometrial cancer * Stage III-IV endometrial cancer with available tissue blocks, including biopsies, hysterectomy specimens and resections of metastatic foci Exclusion Criteria: * A patient record captured outside the time frame from January 2004 to December 2014

Outcomes

Primary Outcomes

progression-free survival

Time frame: 84 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.